106 related articles for article (PubMed ID: 25802012)
1. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
Jaspers A; Baron F; Maertens J; De Prijck B; Schots R; Bonnet C; Hafraoui K; Willems É; Servais S; Fillet G; Beguin Y
Am J Hematol; 2015 Jul; 90(7):E133-4. PubMed ID: 25802012
[No Abstract] [Full Text] [Related]
2. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.
Beguin Y; Maertens J; De Prijck B; Schots R; Seidel L; Bonnet C; Hafraoui K; Willems E; Vanstraelen G; Servais S; Jaspers A; Fillet G; Baron F
Am J Hematol; 2013 Dec; 88(12):990-6. PubMed ID: 23873823
[TBL] [Abstract][Full Text] [Related]
3. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
Krafft A; Breymann C
J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
Koutroubakis IE; Karmiris K; Makreas S; Xidakis C; Niniraki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):421-5. PubMed ID: 16538115
[TBL] [Abstract][Full Text] [Related]
5. [Current recommendations for the treatment of iron deficiency anemia].
Schaefer RM; Huch R; Krafft A;
Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival.
Jaspers A; Baron F; Servais S; Lejeune M; Willems É; Seidel L; Hafraoui K; Bonnet C; Beguin Y
Am J Hematol; 2015 Sep; 90(9):E197-9. PubMed ID: 26113363
[No Abstract] [Full Text] [Related]
7. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
8. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
Pedrazzoli P; Farris A; Del Prete S; Del Gaizo F; Ferrari D; Bianchessi C; Colucci G; Desogus A; Gamucci T; Pappalardo A; Fornarini G; Pozzi P; Fabi A; Labianca R; Di Costanzo F; Secondino S; Crucitta E; Apolloni F; Del Santo A; Siena S
J Clin Oncol; 2008 Apr; 26(10):1619-25. PubMed ID: 18375891
[TBL] [Abstract][Full Text] [Related]
10. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
Nyvad O; Danielsen H; Madsen S
Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
[No Abstract] [Full Text] [Related]
12. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
Lappin TR; Maxwell AP; Johnston PG
Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
[No Abstract] [Full Text] [Related]
13. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
Kelaidi C; Fenaux P
Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
[TBL] [Abstract][Full Text] [Related]
14. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
15. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement.
Cladellas M; Farré N; Comín-Colet J; Gómez M; Meroño O; Bosch MA; Vila J; Molera R; Segovia A; Bruguera J
Am J Cardiol; 2012 Oct; 110(7):1021-6. PubMed ID: 22771376
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.
Glaspy JA
Oncology (Williston Park); 2011 Apr; 25(5):423-4. PubMed ID: 21710839
[No Abstract] [Full Text] [Related]
17. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
Shord SS; Hamilton JM; Cuellar S
J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
19. [Comorbidity: anemia and heart failure].
Mahfoud F; Kindermann I; Kindermann M; Ukena C; Böhm M
Dtsch Med Wochenschr; 2009 Apr; 134(16):825-30. PubMed ID: 19353467
[No Abstract] [Full Text] [Related]
20. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
